论文部分内容阅读
目的观察吉西他滨联合多西他赛治疗晚期老年非小细胞肺癌的临床疗效。方法吉西他滨1000mg/m2,ivgtt,d1,8;多西他赛(国产希存)60mg/m2,ivgtt,d1,每21d为一个周期,至少应用2个周期评价疗效。结果 60例患者,其中CR 5例,PR 14例,SD 17例,PD 24例;总有效率为31.7%(19/60),初治组有效率为37.8%(14/37),复治组有效率为26.1%(6/23);腺癌有效率为36.7%,鳞癌有效率为36.3%;初治与复治、不同的病理类型间有效率差异均无显著性;中位PFS为4.3个月,主要毒副反应为骨髓抑制。结论吉西他滨联合多西他赛方案在老年肺癌患者中有效率高,耐受性可,值得进一步研究。
Objective To observe the clinical efficacy of gemcitabine combined with docetaxel in the treatment of advanced non-small cell lung cancer. Methods Gemcitabine 1000mg / m2, ivgtt, d1,8; docetaxel (domestic hope deposit) 60mg / m2, ivgtt, d1, every 21d for a cycle, at least two cycles evaluated efficacy. Results Among the 60 patients, there were 5 cases of CR, 14 cases of PR, 17 cases of SD and 24 cases of PD. The total effective rate was 31.7% (19/60), the effective rate of initial treatment was 37.8% (14/37) The effective rate was 26.1% (6/23) in group A, 36.7% in adenocarcinoma and 36.3% in squamous cell carcinoma. There was no significant difference in the effective rates between the primary and retreatment groups and the different pathological types. The median PFS 4.3 months, the main side effects of bone marrow suppression. Conclusion The gemcitabine combined with docetaxel is effective and tolerable in elderly patients with lung cancer and deserves further study.